Human Schlafen 11 inhibits influenza A virus production.


Journal

Virus research
ISSN: 1872-7492
Titre abrégé: Virus Res
Pays: Netherlands
ID NLM: 8410979

Informations de publication

Date de publication:
09 2023
Historique:
received: 03 05 2023
revised: 20 06 2023
accepted: 22 06 2023
medline: 7 8 2023
pubmed: 26 6 2023
entrez: 25 6 2023
Statut: ppublish

Résumé

Schlafen (SLFN) proteins are a subset of interferon-stimulated early response genes with antiviral properties. An antiviral mechanism of SLFN11 was previously demonstrated in human immunodeficiency virus type 1 (HIV-1)-infected cells, and it was shown that SLFN11 inhibited HIV-1 virus production in a codon usage-specific manner. The codon usage patterns of many viruses are vastly different from those of their hosts. The codon usage-specific inhibition of HIV-1 expression by SLFN11 suggests that SLFN11 may be able to inhibit other viruses with a suboptimal codon usage pattern. However, the effect of SLFN11 on the replication of influenza A virus (IAV) has never been reported. The induction of SLFN11 expression was observed upon IAV infection. The reduction of SLFN11 expression also promotes influenza virus replication. Moreover, we found that overexpression of SLFN11 could reduce the expression of a reporter gene with a viral codon usage pattern, and the inhibition of viral hemagglutinin (HA) gene was codon-specific as the expression of codon optimized HA was not affected. These results indicate that SLFN11 inhibits the influenza A virus in a codon-specific manner and that SLFN11 may contribute to innate defense against influenza A viruses.

Identifiants

pubmed: 37356582
pii: S0168-1702(23)00124-7
doi: 10.1016/j.virusres.2023.199162
pmc: PMC10410578
pii:
doi:

Substances chimiques

Proteins 0
Interferons 9008-11-1
Codon 0
Antiviral Agents 0
SLFN11 protein, human 0
Nuclear Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

199162

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

PLoS One. 2012;7(5):e36318
pubmed: 22563489
Nucleic Acids Res. 2018 Jan 4;46(D1):D1271-D1281
pubmed: 29106664
Epigenomics. 2017 Jun;9(6):849-862
pubmed: 28403629
Nat Struct Mol Biol. 2018 Nov;25(11):1047-1058
pubmed: 30374083
Nat Commun. 2018 Mar 21;9(1):1165
pubmed: 29563550
Nat Microbiol. 2021 Feb;6(2):234-245
pubmed: 33432153
J Mol Biol. 1982 Jul 15;158(4):573-97
pubmed: 6750137
J Interferon Cytokine Res. 2013 Apr;33(4):206-10
pubmed: 23570387
Cell Host Microbe. 2010 Jun 25;7(6):440-51
pubmed: 20542248
Int Immunol. 2004 Oct;16(10):1535-48
pubmed: 15351786
Immunobiology. 2017 Nov;222(11):979-988
pubmed: 28734654
J Mol Biol. 1981 Sep 25;151(3):389-409
pubmed: 6175758
Immunity. 1998 Nov;9(5):657-68
pubmed: 9846487
Nucleic Acids Res. 2016 Jan 4;44(D1):D184-9
pubmed: 26673694
World J Virol. 2016 May 12;5(2):85-6
pubmed: 27175354
Arch Virol. 2020 May;165(5):1151-1161
pubmed: 32227307
Mol Biol Evol. 1985 Jan;2(1):13-34
pubmed: 3916708
Virus Res. 2005 Apr;109(1):33-7
pubmed: 15826910
BMC Bioinformatics. 2017 Sep 2;18(1):391
pubmed: 28865429
Arch Virol. 2018 Oct;163(10):2883-2888
pubmed: 29987380
PLoS Pathog. 2022 Aug 4;18(8):e1010756
pubmed: 35926068
Nature. 2014 May 29;509(7502):582-7
pubmed: 24870543
J Virol. 2019 Jul 17;93(15):
pubmed: 31118262
Virology. 2021 Mar;555:78-88
pubmed: 33465725
Arch Virol. 2015 Feb;160(2):409-15
pubmed: 25504159
Commun Biol. 2023 May 10;6(1):487
pubmed: 37165099
Nat Chem Biol. 2023 Mar;19(3):301-310
pubmed: 36302897
Mol Biol Evol. 2011 Jun;28(6):1827-34
pubmed: 21216840
Nucleic Acids Res. 2020 Jan 8;48(D1):D1153-D1163
pubmed: 31665479
Viruses. 2022 Feb 21;14(2):
pubmed: 35216035
Cell Biol Int. 2018 Jan;42(1):2-8
pubmed: 28460425
Biol Direct. 2008 Sep 16;3:38
pubmed: 18796141
Biochem Biophys Res Commun. 2008 May 23;370(1):62-6
pubmed: 18355440
J Virol. 2012 May;86(10):5926-30
pubmed: 22398284
J Biol Chem. 2010 Dec 17;285(51):40333-41
pubmed: 20956525
Nucleic Acids Res. 2013 Feb 1;41(3):1914-21
pubmed: 23254333
Mol Cell Proteomics. 2012 Mar;11(3):M111.014050
pubmed: 22278370
Nat Commun. 2022 Aug 11;13(1):4725
pubmed: 35953468
Nature. 2012 Nov 1;491(7422):125-8
pubmed: 23000900
J Gen Virol. 2014 Feb;95(Pt 2):263-277
pubmed: 24225499
Eur J Epidemiol. 2006;21(7):511-9
pubmed: 16858618
EMBO Rep. 2016 Jan;17(1):94-109
pubmed: 26658330
PLoS One. 2013;8(2):e56642
pubmed: 23451064

Auteurs

Kunlakanya Jitobaom (K)

Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand.

Thanyaporn Sirihongthong (T)

Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand.

Chompunuch Boonarkart (C)

Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand.

Supinya Phakaratsakul (S)

Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand.

Ornpreya Suptawiwat (O)

Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Thailand.

Prasert Auewarakul (P)

Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand. Electronic address: prasert.aue@mahidol.ac.th.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH